Royalty Pharma Plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (November 2024)

6 slides from Royalty Pharma's investor presentation, November 2024

  1. Slide 1: Royalty Pharma

    ROYALTY PHARMA

  2. Slide 2: Royalty acquisition

    royalty acquisition November 2024

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or

  4. Slide 4: Niktimvo – addressing significant unmet need in cGvHD

    Niktimvo – addressing significant unmet need in cGvHD 1 2 3 FDA approved for chronic Significant unmet need for Attractive commercial graft vs. host disease steroid-sparing drugs opportunity for Niktimvo Niktimvo is the first FDA approved anti- cGvHD is the leading cause of post- ~17,000 U.S. cGvHD

  5. Slide 5: Niktimvo – addressing significant unmet need in cGvHD

    Niktimvo – addressing significant unmet need in cGvHD • Acquired a synthetic royalty on Syndax/Incyte’s Niktimvo for cGvHD  $350 million upfront payment 13.8% royalty on U.S. sales  Entitled to 13.8% royalty on U.S. sales of Niktimvo  Expected royalty duration to 2038(1)  Projected IRR in the lo

  6. Slide 6: Attractive cGvHD U.S. market dynamics

    Niktimvo – addressing significant unmet need in cGvHD Attractive cGvHD U.S. market dynamics • Significant need for new medicines in cGvHD  Estimated to develop in ~42% of transplant recipients(1)  Nearly 50% of patients require at least three lines of therapy(1) ~17,000 ~4,000-5,000 • Niktimvo: di

Royalty Pharma — Investor Presentation (November 2024) on 6ix